Patents by Inventor Maria Quanz

Maria Quanz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10765758
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 8, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20190314511
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: July 1, 2019
    Publication date: October 17, 2019
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10363317
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: July 30, 2019
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20170298089
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 19, 2017
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • GLUCOSE TRANSPORT INHIBITORS
    Publication number: 20170226081
    Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: July 22, 2015
    Publication date: August 10, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Mélanie HÉROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
  • GLUCOSE TRANSPORT INHIBITORS
    Publication number: 20170210738
    Abstract: The present invention relates to chemical compounds of formula (I) that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: July 22, 2015
    Publication date: July 27, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Bernd BUCHMANN, Iring HEISLER, Thomas MÜLLER, Arwed CLEVE, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9687557
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 27, 2017
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • GLUCOSE TRANSPORT INHIBITORS
    Publication number: 20170037028
    Abstract: The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: December 16, 2014
    Publication date: February 9, 2017
    Inventors: Iring HEISLER, Thomas MÜLLER, Holger SIEBENEICHER, Bernd BUCHMANN, Arwed CLEVE, Judith GÜNTHER, Marcus KOPPITZ, Melanie HEROULT, Roland NEUHAUS, Heike PETRUL, Maria QUANZ-SCHÖFFEL
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20160339107
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: August 10, 2016
    Publication date: November 24, 2016
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9428538
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: August 30, 2016
    Assignees: DNA THERAPEUTICS, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20160046662
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9205099
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: December 8, 2015
    Assignees: DNA THERAPEUTICS, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates
    Publication number: 20130131155
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: June 21, 2011
    Publication date: May 23, 2013
    Applicants: DNA THERAPEUTICS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz